Abstract
Frailty is a multifaceted clinical state associated with accelerated aging and adverse health outcomes. Informed etiological models of frailty hold promise for producing widespread health improvements across the aging population. Frailty is currently measured using aggregate scores, which obscure etiological pathways that are only relevant to subcomponents of frailty. Therefore, we performed the first multivariate genome-wide association study of the latent genetic architecture between 30 frailty deficits, which identified 408 genomic risk loci. Our model included a general factor of genetic overlap across all deficits, plus six novel factors indexing shared genetic signal across specific groups of deficits. Follow-up analyses demonstrated the added clinical and etiological value of the six factors, including predicting frailty in external datasets, divergent genetic correlations with clinically relevant outcomes, and unique underlying biology linked to aging. This suggests nuanced models of frailty are key to understanding its causes and how it relates to worse health.
Competing Interest Statement
Although not directly related to the submitted work, KR has asserted copyright over the Clinical Frailty Scale and (with Olga Theou) the Pictorial Fit-Frail Scale, which are made freely available for non-commercial education and research, as well as non-profit health care with completion of a permission agreement stipulating users will not change, charge for or commercialize the scales. For-profit entities (including pharma) pay a licensing fee, 15% of which is retained by the Dalhousie University Office of Commercialization and Innovation Engagement. After taxes, the remainder of the license fees are donated to the Dalhousie Medical Research Foundation. In the past three years licenses have been negotiated with Rebibus Therapeutics Inc., Cook Research Incorporated, W.L. Gore Associates Inc, Pfizer Inc, Cellcolabs AB, AstraZeneca UK Limited, Qu Biologics Inc, Biotest AG, BioAge Labs Inc, Congenica, Icosavax, Inc. All other authors have no conflicts of interest to declare.
Funding Statement
This study was facilitated by the Deep Dementia Phenotyping (DEMON) Network through the Frailty and Dementia Special Interest Group and is an outcome of a workshop entitled Frailty and Precision Dementia Medicine funded by the University of Exeter Global Partnerships Fund (JMR). This work was funded by grants from the National Institute on Aging (IFF, AEF and ADG; RF1AG073593) and the National Institute of Mental Health (ADG; R01MH120219). The DEMON Network is supported by Alzheimers Research UK (DJL and JMR). DJL is also supported by the National Institute for Health and Care Research Applied Research Collaboration South West Peninsula. The Lothian Birth Cohorts 1936 (LBC 1936) is supported by the Biotechnology and Biological Sciences Research Council, the Economic and Social Research Council [BB/W008793/1], Age UK (The Disconnected Mind Project), the Milton Damerel Trust, and The University of Edinburgh. SRC is supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (221890/Z/20/Z). The English Longitudinal Study of Aging (ELSA) is funded by the National Institute on Aging (R01AG017644), and by UK Government Departments coordinated by the National Institute for Health and Care Research (NIHR). The Prospective Imaging Study of Ageing (PISA) is funded by the National Health and Medical Research Council (Grant ID: APP1095227). JPF is funded by the Legal & General Group (research grant to establish the independent Advanced Care Research Centre at the University of Edinburgh) - legal & General had no role in the conduct of the study, interpretation, or the decision to submit for publication - the views expressed are those of the authors and not necessarily those of legal and general. JDF receives research grant support from the Canadian Institutes of Health Research, the National Multiple Sclerosis Society, MS Canada, and consultation and distribution royalties from MAPI Research Trust. ADR thanks the Natural Sciences and Engineering Research Council of Canada (NSERC) for operating grant RGPIN-2019-05888. KR is supported by Dalhousie University Faculty of Medicine Advancement funding as Clinical Research Professor of Frailty and Aging.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics for LBC1936 was approved by the MultiCentre Research Ethics Committee for Scotland (Wave 1: MREC/01/0/56), the Lothian Research Ethics Committee (Wave 1: LREC/2003/2/29), and the Scotland A Research Ethics Committee (Waves 2, 3, 4 and 5: 07/MRE00/58). Ethical approval for ELSA was gained via the South Central Berkshire Research Ethics Committee (21/SC/0030, 22nd March 2021). The PISA study was approved by the Human Research Ethics Committee (HREC) at QIMR Berghofer Medical Research Institute. All other data used in this study represents existing public datasets of summary data.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The latent frailty factor and pneumonia GWAS summary statistics that were created by this study will be made publicly available on GWAS Catalog upon publication. All of the GWAS summary statistics that were used in this study for the Genomic SEM and genetic correlation analyses are publicly available via the original articles or from PanUKB and FinnGen.
